{"groups":[{"description":"8 milligrams per kilogram (mg/kg) ramucirumab administered as an intravenous (IV) injection on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.","id":"FG000","title":"Ramucirumab + BSC"},{"description":"Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.","id":"FG001","title":"Placebo + BSC"},{"description":"8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.","id":"FG002","title":"Open Label Ramucirumab + BSC"},{"description":"8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.","id":"FG003","title":"Ramucirumab MEE Cohort"},{"description":"Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.","id":"FG004","title":"Placebo MEE Cohort"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"197"},{"groupId":"FG001","numSubjects":"95"},{"groupId":"FG002","numSubjects":"47"},{"groupId":"FG003","numSubjects":"39"},{"groupId":"FG004","numSubjects":"21"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"197"},{"groupId":"FG001","numSubjects":"95"},{"groupId":"FG002","numSubjects":"47"},{"groupId":"FG003","numSubjects":"39"},{"groupId":"FG004","numSubjects":"21"}],"type":"Participants Who Received Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"193"},{"groupId":"FG001","numSubjects":"90"},{"groupId":"FG002","numSubjects":"42"},{"groupId":"FG003","numSubjects":"38"},{"groupId":"FG004","numSubjects":"21"}],"comment":"Completers include participants who had died due to any cause or alive and on study at the end of study, but off treatment.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"c. China Maximized Extended Enrollment: This is an extension phase of the main study, with an additional 60 participants enrolled in China. Safety was monitored and data was reported under AE section.","recruitmentDetails":"1. Main study: Participants who received sorafenib as first-line therapy were randomized to ramucirumab or placebo.\n2. Open-Label Expansion: Participants who were not previously treated with sorafenib were enrolled into this single-arm addenda and treated with ramucirumab. The purpose of this addenda is to monitor safety, and data was reported under AE section.\n\n(Continued...)"}